Objective To determine the rates of germline BRCA1 and BRCA2 mutations in Scottish patients with ovarian cancer, before and after a change in testing policy.
Introduction
Ovarian cancer is the fifth most common female cancer in Europe, with 65 600 new diagnoses and 42 700 deaths in 2012. 1 In Scotland, this equated to 610 new diagnoses and 383 deaths. 2, 3 There is currently no effective screening programme, symptoms are non-specific, and patients usually present with disease that has spread beyond the pelvis. Germline BRCA1 and BRCA2 mutations (hereafter collectively referred to as gBRCA1/2) confer a high risk of epithelial ovarian and breast cancer. The prevalence of gBRCA1/2 mutation in studies of populations (of women with epithelial ovarian cancer) with different genetic backgrounds ranges from 3 to 29% (Table 1) . [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Identification of gBRCA1/2 mutation status in epithelial ovarian cancer has prognostic and predictive benefits for the individual and her family. Mutation carriers with ovarian cancer have longer progression-free times and overall survival, compared with non-carriers, 17, 18 and greater sensitivity to platinum chemotherapy, 19, 20 and to poly (ADPribose) polymerase (PARP) inhibitors. [21] [22] [23] Furthermore, the identification of a gBRCA1/2 mutation enables unaffected relatives to be offered testing for the family mutation, and thus offered risk-reducing surgery or screening for breast and ovarian cancer.
In many countries, the offer of publically funded gBRCA1/2 testing is limited on resource grounds to those with a family history that indicates a specified level of risk (10%, for example). 24 In Scotland, as elsewhere, risk thresholds for full gBRCA1/2 gene testing have fallen over time, as sequencing costs have reduced, from 25 to 10%. Recent studies in a variety of ethnic backgrounds have shown that restricting testing to cases with a family history of breast or ovarian cancer results in 8-54% of mutation carriers remaining undetected. 19, [25] [26] [27] [28] On the basis that the estimated prevalence of gBRCA1/2 mutations in high-grade serous ovarian cancer (HGSOC) may exceed 10% (Table 2) , routine BRCA1 and BRCA2 sequencing was introduced in Scotland for all patients with non-mucinous ovarian cancer in 2012-13. The objective of this study was to determine the rates of BRCA1 and BRCA2 mutation detection in Scottish patients with epithelial ovarian cancer both before and after this change in selection criteria. We also highlight different testing pathways, including one where the initial counselling is performed by the treating oncology team rather than by clinical geneticists.
Methods
Different pathways for delivering testing to all newly diagnosed patients with epithelial ovarian cancer were established in the east and west of Scotland (populations 2.9 and 2.5 million, respectively). In the east of Scotland (centres in Edinburgh, Dundee, and Aberdeen), patients with non-mucinous epithelial ovarian cancer were offered routine testing from 1 November 2012 (Edinburgh), 1 June 2013 (Dundee), and 1 December 2013 (Aberdeen). In Edinburgh and Dundee, patients receive counselling from their medical oncologist, and, after receiving written patient information, give written consent. In Aberdeen, the process is broadly similar, with oncologists introducing the test and arranging blood sampling, but then referring the was used to test for exonic and whole-gene deletions. The DNA of patients found not to have a deleterious BRCA1 or BRCA2 mutation was then sequenced for RAD51C and RAD51D mutations. Patients found to have a deleterious mutation or reported variant of uncertain significance in any of these four genes were subsequently referred to clinical genetics for a face-to-face consultation (as well as any other patients who had a significant family history or who wished for further discussion). Testing for RAD51C and RAD51D mutations in the west of Scotland was restricted to those with two or more family members with a history of ovarian cancer.
Data resulting from the first 18 months of testing following the change in selection criteria were collected from each centre (with the exception of Aberdeen, which instituted the change in practice later and from which 9 months of data were collected) and compared with historical data from the preceding period when access to BRCA1/2 sequencing was dependent upon family history alone.
For each locality, the number and frequency of positive tests was determined for three specific cohorts:
1 'Old criteria' patients: patients sequenced before the change in process (when eligibility for testing was based on family history). The period of testing for these patients was from September 1997 until the date of the change in selection criteria, as specified above. 2 'Prevalent population' patients: the prevalent population of patients who did not fit previous criteria for sequencing but had a diagnosis of HGSOC and were still being reviewed in clinic following the change in selection criteria. 3 'New criteria' patients: patients tested under the new selection process during their first-line treatment.
Results
A total of 631 patients were offered or referred for genetic testing. Of these, there were ten active refusers [declined testing at the time it was offered, either by the medical oncologist in the east (n = 3) or the clinical geneticist in the west (n = 7)], 21 passive refusers (patients in the west who were referred to clinical genetics but did not reply to correspondence), and one patient who was offered testing but died before it could be performed. A total of 599 remaining patients with ovarian cancer were included in the analysis (Table 3) . This included 205 'old criteria' patients and 394 patients tested following the change in selection criteria (236 'new criteria' patients and 158 'prevalent population' patients). In terms of the different pathways for delivering the genetic sequencing, of the 394 patients sequenced following the change in criteria, 251 were sequenced in the east and 143 were sequenced in the west of Scotland. Across Scotland, the frequency of gBRCA1/2 mutation detection was 30.7% in the 'old criteria' patients, 12.7% in the 'prevalent' population, and 13.1% in the 'new criteria' population. In the east of Scotland, the gBRCA1/2 mutation detection rate was 9.4% in the 'prevalent' population and 11.0% in the 'new criteria' population. In the west of Scotland, by comparison, the gBRCA1/2 mutation rate was 17.7% in the 'prevalent' population and 17.3% in the 'new criteria' population. It is worth noting that the frequency of deleterious gBRCA2 mutations in patients in the west of Scotland following the change in selection criteria was strikingly high, at 11.2% in the 'prevalent' population and 13.5% in the 'new criteria' population, compared with 3.1 and 3.9%, respectively, in the east of Scotland. Overall, the annual rate of gBRCA1/2 mutation detection was 4.2 and 20.7 patients per year before and after the change in selection criteria, respectively. Only two mutations in RAD51C/ D were identified following the change in testing criteria, one each in the 'prevalent' and 'new criteria' populations (~1% test positivity rate). Variants of unknown significance were seen in 5.4% (11 of 205, four BRCA1, seven BRCA2) of patients tested with the 'old criteria', 9.4% of the 'prevalent' population (15 of 158, three BRCA1, 12 BRCA2), and 6.4% of the 'new criteria' population (15 of 236, four BRCA1, 11 BRCA2). The Manchester score was recorded for all patients identified to have a pathogenic mutation. 29 Of the 'new criteria' population with gBRCA1/2 mutations, 48% (15/31) had a Manchester score of <15 (Table 4) . Thus, if our new patients had been tested on Manchester score alone, almost half of the mutation carriers would have been missed. In addition, 20 patients with gBRCA1/2 mutations in the prevalent population were identified retrospectively over this 18-month period. None of these had previously been identified as eligible for testing, although interestingly 11 of these patients had a Manchester score of ≥15 when formally assessed by clinical genetics. Only after sequencing became the standard of care were these patients referred. Thus, 39 patients with gBRCA1/2 mutations were identified across Scotland over this 18-month period who would not have been tested if the new policy had not been implemented.
When the histology of the mutation carriers was considered across all three cohorts (Appendix S1), all the mutation carriers were found to have HGSOC (102 out of 518, 19.7%) or epithelial ovarian cancer not otherwise specified (largely from the historical 'old criteria' cohort; 12 out of 44, 27.3%). No deleterious BRCA1/2 mutations were detected in seven patients with carcinosarcoma, nine patients with clear-cell ovarian cancer, or 14 patients with low-grade serous ovarian cancer. In addition, five patients with mucinous tumours, one with a Brenner tumour, and one with a serous tubal intraepithelial carcinoma (STIC) had been sequenced (some in the 'old criteria' cohort). None of these patients harboured deleterious mutations.
The age at diagnosis of all tested patients was recorded. Across all cohorts, 13/114 (11.4%) patients with pathogenic 
Discussion

Main findings
Across Scotland, the frequency of gBRCA1/2 mutation detection was 13.1% in patients presenting with non-mucinous ovarian cancer. The annual rate of gBRCA1/2 mutation detection was 20.7, compared with 4.2 when selection for sequencing was based solely upon family history criteria. The acceptance of the offer of sequencing was high, with only 2% active refusal. In the west of Scotland where a step of active participation in the process was required, an additional 12% of patients passively refused sequencing. Analysis of Manchester scores showed that 48% of new mutation carriers would not have been offered sequencing if selection had been based on family history alone. The gBRCA1/2 mutation rate in the prevalent population was 12.7%, which was surprising as these patients had been overlooked for sequencing when selection was based upon family history criteria, although interestingly 55% of these patients did have a significant family history (Manchester score of >15) when formally assessed by the clinical genetics team. Finally, the incidence of gBRCA1/2 mutations in patients over 70 years of age with non-mucinous ovarian cancer was 8.2%.
Strengths and limitations
The strengths of this study are its size, the fact that it captured all patients offered sequencing across Scotland (thereby limiting the potential for selection bias in tertiary referral centres), and that the data for the majority of patients were retrieved from prospectively collected clinical databases, with case note searching only required in a minority of cases. The limitations of this study are its retrospective nature, the fact that patient satisfaction was not assessed, and the fact that the criteria for selecting patients for sequencing differed slightly between centres (particularly when comparing the east with the west), although this did allow the pros and cons of the different mainstreaming techniques to be highlighted.
Interpretation
At a time when BRCA1/2 mutation status determines access to effective new drugs in the form of PARP inhibitors (olaparib was licensed in 2014 and approved for reimbursement in the UK in 2016), it is imperative that as many patients with ovarian cancer as possible are offered the chance of sequencing. In Scotland, all patients diagnosed with nonmucinous ovarian cancer are now routinely offered germline BRCA1/2 sequencing, an approach enshrined in new national guidelines. 30 Scotland is one of the first countries to offer this service as a national standard of care. The gBRCA1/2 mutation rate in newly diagnosed Scottish patients with ovarian cancer of 13.1% justifies the switch away from family history-based patient selection criteria for sequencing.
Two broad models for routine testing have been implemented, with local variation driven by resource and clinician preference. In the west of Scotland, all patients are referred to Clinical Genetics for counselling and consent before testing, whereas in the east of Scotland oncologists provide genetic counselling at the first clinic visit, obtain written consent, and then offer the test. Patients who are subsequently found to harbour a germline mutation return to Clinical Genetics (in the west), or are then referred to Clinical Genetics in the east, in order that they can receive personal counselling regarding their breast cancer risk, and also in order to facilitate counselling and cascade testing for relatives. In both test models we found that testing was acceptable to patients (although patient satisfaction was not assessed in this study) and that the take-up rates were high. It is noticeable that the take-up rate is lower in the west, where testing requires active patient participation (where patients must reply to an invitation from Clinical Genetics and then attend an appointment or have a telephone consultation before testing can commence). The concept of pre-test counselling being provided by non-geneticists in order to streamline the process so that the genetics team are able to focus on mutation carriers rather than a cohort of patients, many of whom will not carry a mutation, is gathering general acceptance, with other studies demonstrating high levels of patient satisfaction. 31 Previous studies have identified higher mutation rates in patients with ovarian cancer than were identified in the east of Scotland, 19, 26, 32 but broadly similar to those in the west of Scotland. Many of these previous studies recruited patients retrospectively, however, and were based in tertiary referral centres that were not the sole providers of ovarian cancer care in their geographical location. In addition, it was noted that a number of the identified patients could not be enrolled as they had died, thus providing a selection bias towards gBRCA1/2 mutation carriers who have superior survival rates compared with non-carriers. 17 Many of these studies have also been limited by the poor uptake of testing, giving the potential for further selection bias. In the east of Scotland, the sequencing uptake rate was 98.8% (three patients declined testing), suggesting that gBRCA1/2 mutation rates in genuinely unselected patients may be slightly lower than previously suggested. Nevertheless, the case detection rate still met the cost-effectiveness threshold for family benefit, justifying the cost of testing on those grounds alone.
The gBRCA1/2 mutation rate in the prevalent group (12.7%) was higher than expected. We had hypothesised that patients with a strong family history would have been tested under the previous schedule, thus reducing the remaining gBRCA1/2-positive pool in untested patients. An alternative explanation, suggested by the incidence of Manchester scores of ≥15 in patients who had tested positive in the 'prevalent' population, is that the ascertainment of family history by the oncologists was incomplete. By making sequencing routine, the potential for missing patients as a result of inaccurate family history assessment is circumvented.
Historically, RAD51C and RAD51D germline sequencing has been performed in Scotland because of the increased ovarian cancer risk in carriers. 33, 34 With a frequency of mutation of either gene of around 1%, it could be debated whether this is a cost-effective exercise; however, with evidence emerging regarding the PARP inhibitor sensitivity of ovarian tumours harbouring RAD51C mutations, in particular, 35 the results have implications both for the patients and for their families.
The protocol for germline BRCA1 and BRCA2 sequencing of patients with ovarian cancer differs across the UK. Many regions of England, Wales, and Northern Ireland continue to sequence only patients with a significant family history, a small number sequence all patients with non-mucinous ovarian cancer, 31 and others impose age restrictions for germline testing. Here, we show that the rate of germline mutation was 8.2% in patients aged over 70 years, and that 11.4% of all mutation carriers were over 70 years of age at the time of diagnosis. The oldest mutation carrier identified was 84 years old. Our data contrast with a recent study from the east of England, where only one of 86 women over the age of 70 years carried a pathogenic mutation, 36 which led the authors to conclude that testing should be restricted to patients under 70 years of age in the absence of positive family history. Our results are more in line with those of Norquist et al., who identified BRCA1/2 mutations in over 5% of their population aged 70-79 years. 37 Thus, overall, we advocate a policy whereby testing is offered to patients regardless of their age at diagnosis.
Conclusion
We demonstrate that routine nationwide testing of ovarian cancer patients for gBRCA1/2 mutations offers prognostic and predictive information, and meets the cost-effectiveness thresholds already widely in place for UK genetic health care. The strategy detects mutation in 13 per 100 cases, 48% of whom would not be identified through case selection on the basis of family history alone. Testing in the oncology setting, without the requirement for formal pre-test genetic counselling, or a mixed consent model, is feasible, and reduces both the potential for referral bias and the burden upon Clinical Genetics departments. We propose that all women with non-mucinous ovarian cancer should be offered germline BRCA mutation testing as part of routine clinical care prior to the commencement of chemotherapy.
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